Pressure BioSciences, Inc.
PBIO
$0.00
$0.00-50.00%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -25.31% | -20.27% | 14.37% | 58.12% | 10.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -25.31% | -20.27% | 14.37% | 58.12% | 10.59% |
| Cost of Revenue | -41.68% | -48.84% | -41.50% | 131.51% | 92.42% |
| Gross Profit | 3,645.05% | 881.11% | 380.86% | -70.06% | -101.19% |
| SG&A Expenses | 14.26% | 6.75% | 145.22% | 56.89% | 51.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.63% | -5.33% | 73.23% | 63.59% | 53.80% |
| Operating Income | -7.44% | 1.34% | -94.01% | -65.32% | -71.39% |
| Income Before Tax | -35.34% | -63.31% | -82.34% | -54.01% | -42.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.34% | -63.31% | -82.34% | -54.01% | -42.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.34% | -63.31% | -82.34% | -54.01% | -42.00% |
| EBIT | -7.44% | 1.34% | -94.01% | -65.32% | -71.39% |
| EBITDA | -6.12% | 2.00% | -96.52% | -65.77% | -73.35% |
| EPS Basic | 46.79% | 12.14% | -1.59% | 3.55% | 13.61% |
| Normalized Basic EPS | 55.26% | 35.25% | 8.64% | -4.08% | 10.59% |
| EPS Diluted | 46.79% | 12.14% | -1.59% | 3.55% | 13.61% |
| Normalized Diluted EPS | 55.26% | 35.25% | 8.64% | -4.08% | 10.59% |
| Average Basic Shares Outstanding | 144.63% | 124.97% | 102.02% | 76.76% | 64.89% |
| Average Diluted Shares Outstanding | 144.63% | 124.97% | 102.02% | 76.76% | 64.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |